A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.
Metastatic Breast Cancer
DRUG: Pyrotinib, Trastuzumab, Docetaxel|DRUG: Placebo, Trastuzumab, Docetaxel
PFS, Progression Free Survival, Approximately 42 months
AEs+SAEs, Adverse Events and Serious Adverse Events, From the first drug administration to within 28 days for the last treatment|OS, Overall Survival, Up to 2 years|ORR, Objective Response Rate, Approximately 42 months|DoR, Duration of Objective Response, Approximately 42 months|CBR, Clinical Benefit rate, From the start of randomization to 6 months
This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.